The text starts here.

News Release

June 29, 2006
For Print (PDF 149KB)

Eisai Licenses Selective Estrogen Receptor Modulators (SERMs) to Radius

Eisai Co., Ltd. (Headquarters: Tokyo; President & CEO: Haruo Naito) announced today that it signed a license agreement with Radius Health, Inc. (Massachusetts, USA; President: C. Richard Lyttle) for the use of Eisai's new class of selective estrogen receptor modulator (SERM). Radius plans to develop the compound as a new therapeutic drug for osteoporosis and malaise such as hot flashes associated with post-menopausal disorders, etc.

As a part of the agreement, Eisai granted Radius an exclusive license to research, develop, manufacture and sell the compound worldwide, except for Japan; whereas Eisai will maintain the same rights in Japan.
The compound is currently in a stage of preclinical development and Radius will carry out the development of the compound in the licensed territory.
Under the terms of the agreement, Eisai will receive up-front payment, milestone payments and royalties.

The compound is expected to have a curative effect on osteoporosis. At the same time, the new molecular entity is considered to have fewer deleterious peripheral side effects associated with estrogen-like activity. The compound is also expected to provide relief from symptoms such as hot flashes seen at the post-menopausal disorders unlike the currently approved SERMs.

Radius is a bio venture company specializing in pharmaceutical development in the gynecological field. In Europe and the U.S. where estrogen replacement therapy (ERT) is commonly applied for the treatment of menopausal disorders and postmenopausal osteoporosis, Eisai expects to contiribute to the further creation of patients' value through the license to Radius.

[Please see the attached glossaries for reference]

Corporate Communications Department
Eisai Co., Ltd.
TEL: +81-3-3817-5120

< Reference >

< SERM >
SERM is an abbreviation for selective estrogen receptor modulator, one of the non-steroid type compounds that binds with estrogen receptors. The action of Estrogen, one of the female hormones, promotes endometrial hyperplasia (thickening), bone metabolism, blood platelet aggregation, and have been linked to breast and endometrial cancer development.
SERMs are also reported to have many kinds of actions on various organs and tissues, demonstrating activity similar to estrogen in some tissues while acting as estrogen antagonists in other tissues.

[Licensee Company]
< Radius Health, Inc. >
A U.S. bioventure specializing in the gynecological field.(non-public company)
Company name: Radius Health Inc.
President: C. Richard Lyttle
Established: 2003
Location: Cambridge, Massachusetts, U.S.A.